Neurocrine Biosciences Inc (NBIX.OQ)
NBIX.OQ on NASDAQ Stock Exchange Global Select Market
78.18USD
19 Apr 2018
78.18USD
19 Apr 2018
Change (% chg)
$-1.68 (-2.10%)
$-1.68 (-2.10%)
Prev Close
$79.86
$79.86
Open
$79.46
$79.46
Day's High
$79.54
$79.54
Day's Low
$77.56
$77.56
Volume
252,325
252,325
Avg. Vol
320,071
320,071
52-wk High
$92.98
$92.98
52-wk Low
$41.78
$41.78
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | 0.09 | December | 19 Apr 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 5 | 5 | 6 | 6 |
| (2) OUTPERFORM | 6 | 7 | 7 | 7 |
| (3) HOLD | 0 | 0 | 0 | 0 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 1.55 | 1.58 | 1.54 | 1.54 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 9 | 103.94 | 128.43 | 80.00 | 17.08 |
| Quarter Ending Sep-18 | 9 | 102.88 | 141.00 | 77.90 | 31.11 |
| Year Ending Dec-18 | 10 | 379.18 | 425.00 | 327.30 | 156.99 |
| Year Ending Dec-19 | 11 | 627.60 | 680.88 | 564.00 | 328.83 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 10 | 0.09 | 0.39 | -0.19 | -0.56 |
| Quarter Ending Sep-18 | 10 | 0.00 | 0.41 | -0.23 | -0.41 |
| Year Ending Dec-18 | 11 | -0.22 | 0.32 | -0.66 | -1.33 |
| Year Ending Dec-19 | 11 | 1.77 | 2.70 | 0.67 | -0.31 |
| LT Growth Rate (%) | 1 | 160.40 | 160.40 | 160.40 | -- |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Dec-17 | 87.77 | 94.52 | 6.75 | 7.69 |
| Quarter Ending Sep-17 | 29.85 | 60.77 | 30.92 | 103.58 |
| Quarter Ending Jun-17 | 0.66 | 6.34 | 5.67 | 854.21 |
| Quarter Ending Mar-17 | 3.75 | 0.00 | 3.75 | 100.00 |
| Quarter Ending Dec-16 | 4.55 | 0.00 | 4.55 | 100.00 |
| Earnings (per share) | ||||
| Quarter Ending Dec-17 | 0.18 | 0.07 | 0.11 | 61.43 |
| Quarter Ending Sep-17 | -0.48 | -0.13 | 0.35 | -72.96 |
| Quarter Ending Jun-17 | -0.66 | -0.68 | 0.02 | -2.64 |
| Quarter Ending Mar-17 | -0.74 | -0.90 | 0.16 | -22.32 |
| Quarter Ending Dec-16 | -0.56 | -0.51 | 0.05 | -9.61 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 103.94 | 103.94 | 105.38 | 104.15 | 17.08 |
| Quarter Ending Sep-18 | 102.88 | 102.88 | 101.69 | 104.24 | 31.11 |
| Year Ending Dec-18 | 379.18 | 379.18 | 380.06 | 383.95 | 156.99 |
| Year Ending Dec-19 | 627.60 | 627.60 | 624.74 | 625.07 | 328.83 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 0.09 | 0.09 | 0.10 | 0.10 | -0.56 |
| Quarter Ending Sep-18 | 0.00 | 0.00 | -0.01 | 0.01 | -0.41 |
| Year Ending Dec-18 | -0.22 | -0.22 | -0.21 | -0.17 | -1.33 |
| Year Ending Dec-19 | 1.77 | 1.77 | 1.78 | 1.75 | -0.31 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Jun-18 | 0 | 0 | 0 | 1 |
| Quarter Ending Sep-18 | 0 | 0 | 0 | 1 |
| Year Ending Dec-18 | 0 | 0 | 0 | 1 |
| Year Ending Dec-19 | 0 | 0 | 0 | 0 |
| Earnings | ||||
| Quarter Ending Jun-18 | 0 | 0 | 0 | 1 |
| Quarter Ending Sep-18 | 0 | 0 | 0 | 1 |
| Year Ending Dec-18 | 0 | 0 | 0 | 1 |
| Year Ending Dec-19 | 0 | 0 | 0 | 0 |
Earnings vs. 
Estimates- FDA needs more time to review AbbVie, Neurocrine's uterine pain drug
- UPDATE 2-FDA needs more time to review AbbVie, Neurocrine's uterine pain drug
- FDA needs more time to review AbbVie, Neurocrine's uterine pain drug
- CORRECTED-UPDATE 1-FDA needs more time to review AbbVie, Neurocrine's uterine pain drug
- CORRECTED-FDA extends review for AbbVie, Neurocrine's uterine pain drug